KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.12 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.78, a 73.71% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $6.77.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.83, a 87.41% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $30.42, a 380.57% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.65, a 34.08% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $4.02, a 59.80% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.00, a 63.07% decline from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $27.08, a 81.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.12 10-Q · filed 2026-08-07 | |||||||
| 2026-03-31 | $1.78 10-Q · filed 2026-05-08 | |||||||
| 2025-12-31 | $2.65 10-K · filed 2026-03-25 | |||||||
| 2025-09-30 | $2.68 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | $2.68 10-Q · filed 2025-08-08 | |||||||
| 2025-03-31 | $6.77 10-Q · filed 2025-05-09 | |||||||
| 2024-12-31 | $4.02 10-K · filed 2026-03-25 | $4.35 10-K · filed 2025-03-25 | ||||||
| 2024-09-30 | $4.02 10-Q · filed 2024-11-08 | |||||||
| 2023-12-31 | $10.00 10-K · filed 2025-03-25 | $1.11 10-K · filed 2024-03-25 | ||||||
| 2023-09-30 | $1.01 10-Q · filed 2023-11-09 | |||||||
| 2023-06-30 | $29.30 10-Q · filed 2024-08-09 | $3.26 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | $3.83 10-Q · filed 2024-05-10 | |||||||
| 2022-12-31 | $27.08 10-K · filed 2024-03-25 | |||||||
| 2022-09-30 | $27.02 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | $27.08 10-Q · filed 2023-08-08 | $0.68 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | $30.42 10-Q · filed 2023-05-09 | $0.68 10-Q · filed 2022-07-08 | ||||||
| 2021-12-31 | $145.63 10-K · filed 2023-03-23 | $4.91 10-K · filed 2022-04-15 | ||||||
| 2021-09-30 | $170.39 10-Q · filed 2022-11-09 | $5.27 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | $6.12 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | $6.33 10-Q · filed 2021-05-12 | |||||||
| 2020-12-31 | $6.26 10-K/A · filed 2022-07-07 | |||||||
| 2020-09-30 | $6.26 10-Q · filed 2021-11-15 | |||||||
| 2020-06-30 | $6.26 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | $6.46 10-Q · filed 2021-05-12 | |||||||
| 2019-12-31 | $7.11 10-K · filed 2021-03-25 | |||||||
| 2019-09-30 | $7.05 10-Q · filed 2020-11-09 | |||||||
| 2019-06-30 | $7.11 10-Q · filed 2020-08-06 | $0.47 10-Q · filed 2019-08-08 | ||||||
| 2019-03-31 | $7.11 10-Q · filed 2020-05-06 | $0.47 10-Q · filed 2019-05-08 | ||||||
| 2018-12-31 | $8.33 10-K · filed 2020-03-04 | $0.57 10-K · filed 2019-03-01 | ||||||
| 2018-09-30 | $8.30 10-Q · filed 2019-11-07 | $0.57 10-Q · filed 2018-11-13 | ||||||
| 2018-06-30 | $0.55 10-Q · filed 2019-08-08 | $0.57 10-Q · filed 2018-08-03 | ||||||
| 2018-03-31 | $0.55 10-Q · filed 2019-05-08 | $0.57 10-Q · filed 2018-05-11 | ||||||
| 2017-12-31 | $1.42 10-K · filed 2019-03-01 | |||||||
| 2017-09-30 | $1.46 10-Q · filed 2018-11-13 | |||||||
| 2017-06-30 | $1.47 10-Q · filed 2018-08-03 | |||||||
| 2017-03-31 | $1.72 10-Q · filed 2018-05-11 | |||||||
| 2016-09-30 | $2.94 10-Q · filed 2017-11-14 | |||||||
| 2016-06-30 | $3.12 10-Q · filed 2017-08-04 | |||||||
| 2016-03-31 | $3.09 10-Q · filed 2017-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |